About evotec OAI
Evotec OAI has established itself as the partner of choice for drug discovery and development services for the world’s premier pharmaceutical and biotechnology companies, maintaining its leadership role through innovation and unmatched customer service.Their business strategy is clearly focussed on drug discovery. Evotec OAI are world leaders in biology, screening and chemistry services and they provide a comprehensive one-stop shop covering all stages in the drug discovery and development process, or target to IND chain and beyond. In addition, they engage in selected discovery programmes themselves to develop drug candidates for early out-licensing. Their instrument and technology business is now successfully handled by their affiliate, Evotec Technologies.Through use of their innovative proprietary technologies, Evotec OAI have undertaken drug discovery and development services for all of the global top 20 pharma companies. Since 1993 they have completed over 1200 projects for 150 clients and their 2002 revenues stood at €70 million. They have comprehensive state-of-the-art biology and chemistry facilities in Hamburg, Germany and Abingdon, UK and offices in Europe and North America, with representation in Japan. They are listed on Prime Standard, TecDAX 30 index, at Frankfurt stock exchange (as EVT).Evotec OAI is dedicated to returning value to its shareholders and employees through a sustainable business strategy that balances short-term and long-term revenue opportunities.Based on the second quarter 2003 report, financial results for the six months to the end of June 2003 showed:·Revenues increased to EUR 34.8 m (+5%). At constant exchange rates, sales rose by 16%.·EBITDA positive in first half; on track for full-year sales growth of 10-15% and positive EBITDA in 2003.·Operating loss improved by 33% to EUR (10.3) m, excluding amortisation charges by 47% to EUR (4.9) m.·Cash position EUR 16.3 m due to short-term inventory build up.·2003 sales and order book of EUR 67 m as of July 2003, representing 86% of analysts’ revenue forecasts.
Missing: evotec OAI's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: evotec OAI's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Latest evotec OAI News
Feb 11, 2021
Evotec OAI AG, Hamburg, Germany (Neuer Markt: EVT), a supplier of integrated high value added drug discovery services, and SiREEN AG, a drug discovery and development company, announced today the signing of a drug discovery and development agreement to identify and synthesise novel small molecule therapeutics. In this collaboration Evotec OAI will perform assay development, screening and chemical synthesis for up to four targets over the next three years. Initially, SiREEN will select targets from which Evotec OAI will develop biological assays and perform screening using their high-quality lead discovery library to identify novel scaffolds. Additionally, SiREEN will access Evotec OAI's leading chemical synthesis platform to support the development of protein family specific compound libraries. Equally, SiREEN's technologies SiREENize and SiREENscreen can be used in Evotec OAI's processes with the aim to define highly selective lead compounds. The agreement combines both companies' core technologies and allows either party to access these for use in their drug discovery and service offerings respectively. For the initial programme SiREEN will pay to Evotec OAI fees for services. In addition, Evotec OAI will receive an equity stake in SiREEN. Under the terms of the agreement both companies will receive milestone and royalty payments for the services provided. The agreement also includes an option to extend the collaboration beyond discovery to drug development programs. Additionally, over the next three years SiREEN will grant Evotec OAI access to proprietary technologies to augment Evotec OAI's comprehensive drug discovery platform. "SiREEN's innovative drug discovery technology will add further value to our comprehensive Target-to-IND process," said Dr. Timm-H. Jessen, Chief Scientific Officer of Evotec OAI. "We are delighted that both companies will collaborate to enhance the search for novel therapeutics." "We strongly believe that the combination of Evotec OAI's validated drug discovery platform and SiREEN's novel technologies SiREENize and SiREENscreen will boost the efficiency of the drug discovery and development process", said Dr. Michael Schäffer, SiREENs Chief Executive Officer. "There is a perfect fit between SiREEN and Evotec OAI and we are looking forward to strengthen our collaboration in the future." Source: Evotec
evotec OAI Frequently Asked Questions (FAQ)
When was evotec OAI founded?
evotec OAI was founded in 1991.
Where is evotec OAI's headquarters?
evotec OAI's headquarters is located at 151 Milton Park, Abingdon.
What is evotec OAI's latest funding round?
evotec OAI's latest funding round is Acquired.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.